Agios gains $20M to extend April cancer deal with Celgene

As a result of steady progress in the first 18 months of collaboration, Celgene and Agios Pharmaceuticals have extended by a year the initial period of exclusivity covered by a 2010 deal to develop therapies that target cancer metabolism. The move triggers a $20 million payment to Agios.